Physician profile
Mark C Skains
NPI 1679794275
$3,866.39
in general payments reported to CMS, 2019-2025
27 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $186 · 2021: $216 · 2022: $432 · 2023: $1,147 · 2024: $1,016 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.06 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $877.86 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $469.86 | 2019-2025 | |
| Abbott Laboratories | $249.26 | 2019-2024 | Optis, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.51 | 2019-2025 | Jardiance |
| Pfizer INC. | $246.24 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $237.53 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $234.89 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $190.93 | 2019-2024 | Watchman Flx, Watchman Access System |
| Atricure, INC. | $151.40 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $115.61 | 2022-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $94.13 | 2019-2024 | |
| Edwards Lifesciences Corporation | $89.64 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.99 | 2019-2024 | Lifevest |
| Philips North America LLC | $70.73 | 2024 | (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $64.12 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $62.47 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $59.37 | 2021-2022 | |
| Cvrx, INC. | $57.93 | 2023 | Barostim Neo System |
| Scpharmaceuticals INC. | $44.14 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $42.63 | 2021-2024 | Wainua |
| Alnylam Pharmaceuticals INC. | $35.08 | 2024-2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $31.27 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $30.78 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $29.62 | 2022 | |
| Portola Pharmaceuticals, LLC | $23.34 | 2019 | |
| Kestra Medical Technology Services, INC. | $16.69 | 2024 | Assure Wcd |
| Heartflow, INC. | $13.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Skains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.